Newsroom | 22707 results

LAUSANNE, Switzerland--(BUSINESS WIRE)--Testmate Health Partners with Intermountain Health to Expand Access to Rapid STI Testing...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (ufficio centrale: Chuo-ku, Tokyo, Presidente: Toshiaki Nagasato) ha annunciato oggi un investimento in partecipazioni strategiche in Lyric Bio, Inc. (ufficio centrale: San Carlos, USA, fondato dal CEO: Kayj Shannon e dalla Chief Scientific Officer Melanie Matheu). Grazie a questo investimento, Meiji Seika Pharma desidera accelerare lo sviluppo di fase iniziale dell'innovativa piattaforma di Lyric Bio per la produzione di immoglobulina umana...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (siège social : Chuo-ku, Tokyo ; président : Toshiaki Nagasato) a annoncé aujourd’hui un investissement stratégique dans Lyric Bio, Inc. (siège social : San Carlos, États-Unis ; fondateurs : Kayj Shannon [directeur général] et Melanie Matheu [directrice scientifique]). Cet investissement permettra à Meiji Seika Pharma d’accélérer le développement précoce de la plateforme innovante de Lyric Bio pour la production d’immunoglobulines humaines (I...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. ( Hauptgeschäftsstelle: Chuo-ku, Tokio, President: Toshiaki Nagasato) hat heute eine strategische Kapitalbeteiligung an Lyric Bio, Inc. ( Hauptgeschäftsstelle: San Carlos, USA, gegründet von Chief Executive Officer: Kayj Shannon und Chief Scientific Officer Melanie Matheu) bekannt gegeben. Meiji Seika Pharma möchte mit dieser Investition die frühe Entwicklungsphase der innovativen Plattform von Lyric Bio zur Herstellung von humanem Immunglobu...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (sede central: Chuo-ku, Tokio; presidente: Toshiaki Nagasato) anunció hoy que realizará una inversión estratégica de capital en Lyric Bio, Inc. (sede central: San Carlos, EE. UU.; fundada por su directora ejecutiva, Kayj Shannon, y su directora científica, Melanie Matheu). Con esta inversión, Meiji Seika Pharma busca impulsar el desarrollo de la etapa inicial de la innovadora plataforma de Lyric Bio que se destinará a la producción de inmunog...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdkantoor: Chuo-ku, Tokio, president: Toshiaki Nagasato) heeft vandaag een strategische aandeleninvestering in Lyric Bio, Inc. (hoofdkantoor: San Carlos, VS, opgericht door Chief Executive Officer: Kayj Shannon en Chief Scientific Officer Melanie Matheu) aangekondigd. Met deze investering wil Meiji Seika Pharma de vroege ontwikkeling van het innovatieve platform van Lyric Bio voor de productie van humaan immunoglobuline (IVIg) versnellen,...

GREENSBORO, N.C.--(BUSINESS WIRE)--Mollie Williams, DrPH, MPH, has joined Mission Mobile Medical Group as Vice President of Evidence and Insights. Williams is recognized as one of the foremost authorities in mobile health, bringing decades of experience in building the systems, measurements, and collaborations needed to clearly show how community health programs improve outcomes and reduce costs. Dr. Williams joins Mission Mobile Medical after nearly a decade at Harvard Medical School, where sh...

MEDFORD, Mass. & PUNE, India--(BUSINESS WIRE)--Sunflower Therapeutics announces a major installation of Daisy Petal™ Systems at the Serum Institute of India....

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma invests in Lyric Bio to advance IVIg innovation, develop donation-free production, and ensure a stable immunoglobulin supply....

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced an update to its professional and general liability (“PLGL”) reserves, following its annual, third-party actuarial review of anticipated PLGL costs. This update reflects higher expected expenses associated primarily with patient-related litigation. As a result, the Company now expects full-year 2025 Adjusted EBITDA in the range of $601 million to $611 million, compared to...